Regeneron vaults ahead of Amgen in race to market cholesterol drug

January 26, 2015 11:54 AM

4 0

Regeneron vaults ahead of Amgen in race to market cholesterol drug

Regeneron Pharmaceuticals REGN said Monday U.S. health regulators have accepted its application to review a potent cholesterol drug on a priority basis, potentially giving it the upper hand in a fierce race with Amgen Inc AMGN to bring a new medicine from the promising class to market.

Regeneron, which is developing the drug, alirocumab, in partnership with Sanofi-Aventis SA SNYNF , said the target date for a Food and Drug Administration approval decision was July 24, following a six-month review period.

Also read: Pebble Discontinuing Smartwatches After Its Sale to Fitbit

Read more

To category page

Loading...